9 results
To measure the effectiveness of intrathecal methylprednisolone and lidocaine on reducing PHN. Measurement of mthylprednisolone concentrations in cerebrospinal fluid (Part I only).
1. To investigate the safety and tolerability of single oral doses of NS11821 in healthy male subjects and estimate a maximum tolerated dose.2. To investigate the pharmacokinetics (PK) of single ascending oral doses of NS11821.
The aim of the study is to evaluate the efficacy and safety of three IV treatment regimens of sifalimumab in adult subjects with chronic, moderately-to-severely active SLE with an inadequate response to SOC SLE (Standard Of Care treatment for SLE).…
To evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapies.The primary efficacy endpoint of this study is * Overall survivalThe secondary efficacy endpoints of this…
To describe the pharmacokinetic (PK) profile and effectiveness of sarilumab in patients with sJIA in order to identifythe dose and regimen for continued development in this population.
2. Objective of the study (in English): The main purpose of this study is to determine the anti-tumor effects of TAR-200 + IV cetrelimab (cohort 1) and IV cetrelimab alone (cohort 2).The secondary objectives are to evaluate the safety and…
Cohorts 1, 2, and 3 only:The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3)…
The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS…
Main objectives:• To evaluate whole body distribution of 89Zr-Df-crefmirlimab in cancer patients prior to and during treatment with an anti-PD-1 antibody.• To evaluate pharmacokinetics (PK) of 89Zr-Df-crefmirlimab in patients prior to and during…